Quince therapeutics receives notice of allowance covering innovative method of use for lead indication ataxia-telangiectasia

South san francisco, calif.--(business wire)---- $qncx #biotech--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced that the u.s. patent and trademark office (uspto) has issued a notice of allowance for u.s. patent application no. 17/083,771 entitled process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes.
QNCX Ratings Summary
QNCX Quant Ranking